Novartis sews up Elidel off-label probe with $19.9M deal

Novartis ($NVS) agreed to pay $19.9 million to wrap up federal and state allegations that it marketed its eczema cream Elidel for off-label use. The settlement is a small fraction of other Big Pharma marketing settlements, which have grown into the billions. Report